tiprankstipranks
Trending News
More News >
ZyVersa Therapeutics (ZVSA)
OTHER OTC:ZVSA
US Market
Advertisement

ZyVersa Therapeutics (ZVSA) Price & Analysis

Compare
200 Followers

ZVSA Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

11.03%0.16%0.36%88.45%
11.03%
Insiders
0.36% Other Institutional Investors
88.45% Public Companies and
Individual Investors

ZVSA FAQ

What was ZyVersa Therapeutics’s price range in the past 12 months?
ZyVersa Therapeutics lowest stock price was $0.12 and its highest was $4.20 in the past 12 months.
    What is ZyVersa Therapeutics’s market cap?
    ZyVersa Therapeutics’s market cap is $696.90K.
      When is ZyVersa Therapeutics’s upcoming earnings report date?
      ZyVersa Therapeutics’s upcoming earnings report date is Aug 25, 2025 which is in 33 days.
        How were ZyVersa Therapeutics’s earnings last quarter?
        Currently, no data Available
        Is ZyVersa Therapeutics overvalued?
        According to Wall Street analysts ZyVersa Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does ZyVersa Therapeutics pay dividends?
          ZyVersa Therapeutics does not currently pay dividends.
          What is ZyVersa Therapeutics’s EPS estimate?
          ZyVersa Therapeutics’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does ZyVersa Therapeutics have?
          ZyVersa Therapeutics has 4,873,456 shares outstanding.
            What happened to ZyVersa Therapeutics’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of ZyVersa Therapeutics?
            Currently, no hedge funds are holding shares in ZVSA

            Company Description

            ZyVersa Therapeutics

            ZyVersa Therapeutics (ZVSA) is a clinical stage specialty biopharmaceutical company focused on developing innovative therapies to address unmet needs in the areas of renal and inflammatory diseases. The company leverages its proprietary technologies to advance a portfolio of drug candidates aimed at improving patient outcomes and quality of life. ZyVersa's core product candidates include VAR 200 for kidney diseases and IC 100 for inflammatory conditions, which are in various stages of clinical development.
            Similar Stocks
            Company
            Price & Change
            Follow
            Scinai Immunotherapeutics
            Protagenic Therapeutics
            ELEVAI Labs Inc.
            Popular Stocks
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis